Ekterly-Sebetralstat
Ekterly is the first and only oral, on-demand therapy for hereditary angioedema (HAE) attacks in patients aged 12 and older. It works by inhibiting plasma kallikrein, preventing excessive bradykinin production to reduce swelling rapidly. Approved in the U.S. and U.K. in 2025, Ekterly offers fast relief, convenient oral dosing, and a major advance over injectable […]
Zegfrovy-Sunvozertinib
Zegfrovy is a significant breakthrough in precision oncology for patients with non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations. It sets a new benchmark for patients with few therapy alternatives by combining clinically significant efficacy, oral convenience, and highly selective EGFR inhibition. Its quick approval highlights the critical need for efficient […]
Ibtrozi-Taletrectinib
Ibtrozi is a targeted oral therapy for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. This selective ROS1 tyrosine kinase inhibitor received FDA approval in June 2025 with breakthrough therapy designation. Features enhanced CNS penetration for improved efficacy against brain metastases compared to earlier ROS1 inhibitors.
Tryptyr-Acoltremon
Tryptyr is an oral neuroactive steroid modulator designed to treat dry eye disease. It acts on nervous system pathways to relieve symptoms and improve eye comfort.
Avmapki Fakzynja Co-Pack-Avutometinib And Defactinib
Avmapki Fakzynja combines two oral kinase inhibitors for adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer after prior systemic therapy. It targets both MEK and FAK pathways to help control tumor growth in patients with limited treatment options.
Dawnzera-Donidalorsen
Dawnzera is an RNA-targeted antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It works by selectively reducing prekallikrein production, thereby lowering bradykinin formation, to significantly reduce the frequency and severity of swelling episodes. The drug is administered via a subcutaneous autoinjector every 4 weeks, […]
